Ciprofloxacin 0.3%/dexamethasone 0.1% topical drops for the management of otic infections

Peter S. Roland, Michael Wall

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The American Academy of Otolaryngology - Head and Neck Surgery has recommended that, where possible, infections of the external auditory canal and middle ear be treated with topical preparations. The advantages of topical therapy include i) excellent efficacy; ii) decreased risk of systemic side effects; iii) less likelihood of selecting for resistant strains of microorganisms; and iv) lack of potential for ototoxicity. One advantage of topical therapy arises as a consequence of a very high concentration of antibiotic in topical preparations reaching the site of infection. Ciprofloxacin 0.3%/ dexamethasone 0.1% (Ciprodex®) is the only ototopical drop approved for use in both the middle ear and external auditory canal that combines a fluoroquinolone with a steroid. At 0.3% (3000 mcg/ml), the ciprofloxacin concentration of Ciprodex exceeds the MIC of virtually all relevant organisms by a very considerable margin. The clinical efficacy of ciprofloxacin/dexamethasone suspension has been demonstrated in several large prospective clinical trials. It has been consistently equal to or superior to comparator drugs. The authors believe that the use of topical ciprofloxacin/dexamethasone will increase as the advantages of fluoroquinolone/steroid combination therapy become more widely recognized.

Original languageEnglish (US)
Pages (from-to)3129-3135
Number of pages7
JournalExpert Opinion on Pharmacotherapy
Volume9
Issue number17
DOIs
StatePublished - Dec 2008

Fingerprint

Ciprofloxacin
Dexamethasone
Ear
Infection
Ear Canal
Fluoroquinolones
Middle Ear
Steroids
Otolaryngology
Suspensions
Neck
Therapeutics
Head
Clinical Trials
Anti-Bacterial Agents
Pharmaceutical Preparations

Keywords

  • Ciprodex
  • Ciprofloxacin
  • Dexamethasone
  • Draining ear
  • Ear drops
  • Otitis externa
  • Otitis media
  • Otorrhea
  • Ototopical
  • Tympanostomy tube

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Ciprofloxacin 0.3%/dexamethasone 0.1% topical drops for the management of otic infections. / Roland, Peter S.; Wall, Michael.

In: Expert Opinion on Pharmacotherapy, Vol. 9, No. 17, 12.2008, p. 3129-3135.

Research output: Contribution to journalArticle

@article{efc1d18b40de448dace64184a0f2431e,
title = "Ciprofloxacin 0.3{\%}/dexamethasone 0.1{\%} topical drops for the management of otic infections",
abstract = "The American Academy of Otolaryngology - Head and Neck Surgery has recommended that, where possible, infections of the external auditory canal and middle ear be treated with topical preparations. The advantages of topical therapy include i) excellent efficacy; ii) decreased risk of systemic side effects; iii) less likelihood of selecting for resistant strains of microorganisms; and iv) lack of potential for ototoxicity. One advantage of topical therapy arises as a consequence of a very high concentration of antibiotic in topical preparations reaching the site of infection. Ciprofloxacin 0.3{\%}/ dexamethasone 0.1{\%} (Ciprodex{\circledR}) is the only ototopical drop approved for use in both the middle ear and external auditory canal that combines a fluoroquinolone with a steroid. At 0.3{\%} (3000 mcg/ml), the ciprofloxacin concentration of Ciprodex exceeds the MIC of virtually all relevant organisms by a very considerable margin. The clinical efficacy of ciprofloxacin/dexamethasone suspension has been demonstrated in several large prospective clinical trials. It has been consistently equal to or superior to comparator drugs. The authors believe that the use of topical ciprofloxacin/dexamethasone will increase as the advantages of fluoroquinolone/steroid combination therapy become more widely recognized.",
keywords = "Ciprodex, Ciprofloxacin, Dexamethasone, Draining ear, Ear drops, Otitis externa, Otitis media, Otorrhea, Ototopical, Tympanostomy tube",
author = "Roland, {Peter S.} and Michael Wall",
year = "2008",
month = "12",
doi = "10.1517/14656560802489262",
language = "English (US)",
volume = "9",
pages = "3129--3135",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "17",

}

TY - JOUR

T1 - Ciprofloxacin 0.3%/dexamethasone 0.1% topical drops for the management of otic infections

AU - Roland, Peter S.

AU - Wall, Michael

PY - 2008/12

Y1 - 2008/12

N2 - The American Academy of Otolaryngology - Head and Neck Surgery has recommended that, where possible, infections of the external auditory canal and middle ear be treated with topical preparations. The advantages of topical therapy include i) excellent efficacy; ii) decreased risk of systemic side effects; iii) less likelihood of selecting for resistant strains of microorganisms; and iv) lack of potential for ototoxicity. One advantage of topical therapy arises as a consequence of a very high concentration of antibiotic in topical preparations reaching the site of infection. Ciprofloxacin 0.3%/ dexamethasone 0.1% (Ciprodex®) is the only ototopical drop approved for use in both the middle ear and external auditory canal that combines a fluoroquinolone with a steroid. At 0.3% (3000 mcg/ml), the ciprofloxacin concentration of Ciprodex exceeds the MIC of virtually all relevant organisms by a very considerable margin. The clinical efficacy of ciprofloxacin/dexamethasone suspension has been demonstrated in several large prospective clinical trials. It has been consistently equal to or superior to comparator drugs. The authors believe that the use of topical ciprofloxacin/dexamethasone will increase as the advantages of fluoroquinolone/steroid combination therapy become more widely recognized.

AB - The American Academy of Otolaryngology - Head and Neck Surgery has recommended that, where possible, infections of the external auditory canal and middle ear be treated with topical preparations. The advantages of topical therapy include i) excellent efficacy; ii) decreased risk of systemic side effects; iii) less likelihood of selecting for resistant strains of microorganisms; and iv) lack of potential for ototoxicity. One advantage of topical therapy arises as a consequence of a very high concentration of antibiotic in topical preparations reaching the site of infection. Ciprofloxacin 0.3%/ dexamethasone 0.1% (Ciprodex®) is the only ototopical drop approved for use in both the middle ear and external auditory canal that combines a fluoroquinolone with a steroid. At 0.3% (3000 mcg/ml), the ciprofloxacin concentration of Ciprodex exceeds the MIC of virtually all relevant organisms by a very considerable margin. The clinical efficacy of ciprofloxacin/dexamethasone suspension has been demonstrated in several large prospective clinical trials. It has been consistently equal to or superior to comparator drugs. The authors believe that the use of topical ciprofloxacin/dexamethasone will increase as the advantages of fluoroquinolone/steroid combination therapy become more widely recognized.

KW - Ciprodex

KW - Ciprofloxacin

KW - Dexamethasone

KW - Draining ear

KW - Ear drops

KW - Otitis externa

KW - Otitis media

KW - Otorrhea

KW - Ototopical

KW - Tympanostomy tube

UR - http://www.scopus.com/inward/record.url?scp=57549096144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57549096144&partnerID=8YFLogxK

U2 - 10.1517/14656560802489262

DO - 10.1517/14656560802489262

M3 - Article

C2 - 19013865

AN - SCOPUS:57549096144

VL - 9

SP - 3129

EP - 3135

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 17

ER -